Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions
Summary
Augustine Therapeutics will present a late-breaking poster at the ADA 2026 Scientific Sessions in New Orleans. The poster will share in vivo efficacy data for one of its HDAC6 inhibitor candidates in a mouse model of heart failure with preserved ejection fraction. The company positions the program as part of its broader effort to develop therapies for cardiometabolic, neuromuscular, and neurodegenerative diseases. Augustine also notes that it raised a €78 million Series A in 2025 to advance its pipeline toward the clinic.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected